1335 related articles for article (PubMed ID: 17182241)
41. Darbepoetin alfa: a review of its use in the treatment of anaemia in patients with cancer receiving chemotherapy.
Siddiqui MA; Keating GM
Drugs; 2006; 66(7):997-1012. PubMed ID: 16740021
[TBL] [Abstract][Full Text] [Related]
42. Treatment of chemotherapy-related anemia with erythropoietic agents: current approaches and new paradigms.
Waltzman RJ
Semin Hematol; 2004 Oct; 41(4 Suppl 7):9-16. PubMed ID: 15768474
[TBL] [Abstract][Full Text] [Related]
43. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
Waltzman R; Croot C; Justice GR; Fesen MR; Charu V; Williams D
Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
[TBL] [Abstract][Full Text] [Related]
44. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
Montoya VP; Xie J; Williams D; Woodman RC; Wilhelm FE
Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
[TBL] [Abstract][Full Text] [Related]
45. [Epoetin beta for the treatment of chemotherapy-induced anaemia in solid and haematological malignancies. Results of an open-label, multicentric clinical trial].
Spaëth D
Bull Cancer; 2010 Aug; 97(8):969-78. PubMed ID: 20538545
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
47. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
Mark TL; McKenzie RS; Fastenau J; Piech CT
Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
[TBL] [Abstract][Full Text] [Related]
48. Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
Bogdanos J; Karamanolakis D; Milathianakis K; Repousis P; Chloraki-Bobota A; Majed H; Pagalou-Thoua E; Tsintavis A; Koutsilieris M
Anticancer Res; 2004; 24(3b):1957-61. PubMed ID: 15274384
[TBL] [Abstract][Full Text] [Related]
49. Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study.
de Castro J; Belda-Iniesta C; Isla D; Dómine M; Sánchez A; Batiste E; Barón MG
Lung Cancer; 2008 Feb; 59(2):211-8. PubMed ID: 17875340
[TBL] [Abstract][Full Text] [Related]
50. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
51. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
[TBL] [Abstract][Full Text] [Related]
52. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
[TBL] [Abstract][Full Text] [Related]
53. Management of anemia in patients with cancer.
Steensma DP
Curr Oncol Rep; 2004 Jul; 6(4):297-304. PubMed ID: 15161584
[TBL] [Abstract][Full Text] [Related]
54. Darbepoetin alfa in the treatment of chemotherapy-induced anaemia.
Wauters I; Vansteenkiste J
Expert Opin Biol Ther; 2009 Feb; 9(2):221-30. PubMed ID: 19236252
[TBL] [Abstract][Full Text] [Related]
55. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
56. Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia.
Lüthi F; Pless M; Leyvraz S; Biedermann B; Müller E; Hermann R; Monnerat C
Support Care Cancer; 2010 Dec; 18(12):1515-20. PubMed ID: 19921283
[TBL] [Abstract][Full Text] [Related]
57. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
Henry DH
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
59. [Standards, options and recommendations for the use of recombinant erythropoietin (epoietin alpha and beta darbepoietin-alpha, EPO) in the management of anaemia in oncology for patient undergoing radiotherapy-update 2003].
Marchal C; Spaeth D; Casadevall N; Daouphars M; Marec-Berard P; Fabre N; Haugh M;
Cancer Radiother; 2004 Jun; 8(3):197-206. PubMed ID: 15260007
[TBL] [Abstract][Full Text] [Related]
60. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon).
Glaspy J; Beguin Y
Oncology; 2005; 69 Suppl 2():8-16. PubMed ID: 16244505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
